Photo: Pixabay

GlobeNewsWire.com

Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced its participation at the American Diabetes Association (ADA) 82nd Scientific Sessions® meeting in New Orleans from June 3-7, 2022. There will be two data presentations focused on the value of KidneyIntelX™ in care for adult patients with type 2 diabetes (T2D) and early-stage chronic kidney disease (CKD), including a late-breaking ePoster and an oral presentation.

The ePoster, “Clinical Utility of KidneyIntelX on Patients with Early-Stage Diabetic Kidney Disease—A Real-World Evidence Study” will be the first time Mount Sinai Health System is presenting data from its real-world evidence clinical utility study with Renalytix in 1,112 patients tested with KidneyIntelX. The poster will be presented to in-person and virtual conference attendees on June 5, at 12:00 p.m. CT, with commentary on behalf of the study investigators by Joji Tokita, M.D., Clinical Director, Division of Nephrology and Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai. Michael J. Donovan, Ph.D., M.D., Chief Medical Officer of Renalytix, will be available on-site for commentary.

A second oral presentation, “KidneyIntelX Association with Clinical Outcomes in Diabetic Kidney Disease” will be on June 3, at 4:45 p.m. CT by Steven G. Coca, D.O., M.S., Icahn School of Medicine at Mount Sinai, and Co-Founder of Renalytix.

“We’ve seen the ADA’s dedication to improving kidney health in people with T2D firsthand as part of our ongoing collaboration to develop a care pathway to advance screening, diagnosis and early-stage treatment for the 40% of these patients who will develop CKD,” said Tom McLain, President, Renalytix. “Chronic kidney disease can lead to significant complications for diabetes patients including cardiovascular disease and heart failure, and when left untreated can lead to dialysis and kidney transplant. Our mission is to give healthcare professionals new tools to understand an individual’s risk for rapid progression of CKD, allowing them to appropriately prescribe therapeutics and to utilize specialist consultation when necessary. We look forward to joining other industry leaders at this year’s Scientific Sessions in showcasing our research efforts.”

Renalytix will be exhibiting at booth #1803. The ePoster (Board No. 14) and oral presentation (Board No. 19) abstracts are available to conference attendees and public online through the 2022 ADA Scientific Sessions Online Planner.

KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to Renalytix. Mount Sinai and Mount Sinai faculty, including Dr. Coca, have a financial interest in Renalytix. Mount Sinai also has representation on the Renalytix Board of Directors.